ResMed is the third most shorted healthcare stock in the S&P500, with nearly 6% of the float short, behind Moderna and DaVita.
If the company continues to deliver and hit even something in the ballpark of its its longer-term aspirations, there's plenty of upside as more shorts will be forced to cover their positions, even after the great run we have had since the lows of last year.
New 52w high today, and on track for meeting my expectation of forming new all-time highs beyond $40 imminently. It's taking longer than I expected though following a typically strong quarterly.